Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
| The Manila Times
PHILADELPHIA, July 06, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. ('Context” or the 'Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging ('TCE”) bispecific antibodies for solid tumors, today announced that the Company was added to the small-cap Russell 2000® and the broad-market Russell 3000® Indexes, effective at the close of U.S. equity markets on June 26, 2026.